Advanced Precision Therapies For Cancer

SNAP Technology Platform

Novel precision medicine technology platform designed to transform the treatment of cancer by addressing the challenges of first-generation cell therapies targeting solid tumors

Best-in-Class Therapeutic Cancer Vaccines

Lead Program: SNAPduo 101 peptide cancer vaccine for virus-associated cancers will begin clinical testing in 2026

Proprietary Specific Neo-Antigen Peptides (SNAP) Technology Platform

Developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network.  

Dr. Sharma is one of the nation’s leading experts in creating anti-cancer drugs and has recently been named director of HonorHealth Research Institute’s new Center for Translational Science.

Our SNAP Technology Platform is a Major Step Forward for Targeted Therapy

  • High-impact technology translating neoantigen identification to the clinic
  • Direct biological confirmation of immunogenicity for individual neoantigens
  • Only platform that identifies functionally validated both HLA Class I and II antigens for cancer vaccines
  • Differentiated patient-specific treatment for both immunological “hot” and “cold” tumors

Team

Our Team has decades of proven experience and leadership in biopharma; supported by a network of expert advisors.

Kenneth Carter, PhD

Co-Founder & Executive Chairman

Sunil Sharma, MD, FACP, MBA

Co-Founder & CMO

Juan Montesinos, MD MS

Co-Founder & COO

Michael King, MBA

Co-Founder & CFO

Daniel-Paul Bednarík, PhD

CTO

Raffaela Soldi, PhD

VP of Research

Alexis Weston

Director of Strategy

© Black Canyon Bio, Inc. 2024 All Rights Reserved.